ArticleAmerican journal of men's health2017
Eclipsed by the Prostate: Expanding Testicular Cancer Scholarship Through Years of Potential Life Lost and Economic Productivity.
Article in American journal of men's health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Men's health has been generalized as prostate cancer (PCa) with a supporting cast of other health issues, such as testicular cancer (TCa). As a result, research and scholarship in these supporting topical areas may not receive appropriate attention.This may possibly lead to disease burden indicators failing to comprehensively assess overall affect from a specific outcome within the population. The following commentary provides an example of years of potential life lost (YPLL) and economic productivity as it relates to TCa to encourage diversity in male health research and scholarship topical areas. Overall incidence and mortality rates overwhelmingly support a disparate burden from PCa as compared to other male-specific outcomes, specifically, TCa. When factoring in YPLL and lost economic activity as a result of early death, that disparity essentially dissipates. This discussion will provide an alternative disposition on how males are affected by PCa and TCa. Although PCa has much larger mortality and incidence rates compared to TCa, the amount of life a man potentially lo ses (nearly quadrupled) if he would die of TCa as compared to PCa assists in balancing out the disparate aforementioned burden. Suggestions are offered to encourage scholarship attention equity as well as implications for future research in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.